Introduction {#sec1}
============

Pustular psoriasis is a well-known form of psoriasis, the main variants of which are acute generalized pustular psoriasis (GPP), including GPP of pregnancy, annular pustular psoriasis (APP), acrodermatitis continua of Hallopeau (ACH), and palmoplantar pustulosis (PPP). APP is a rare entity that presents as recurring annular or figurate erythematous plaques with peripheral pustules and scales that expand centrifugally.

Secukinumab is a novel human monoclonal antibody that inhibits interleukin (IL)-17A. Secukinumab was recently approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. We present the first report to our knowledge of an APP case successfully treated with secukinumab.

Case {#sec2}
====

A 29-year-old white woman presented with a 22-year history of severe pustular eruptions arising on erythematous skin. Most of the pustular eruptions had annular morphology although occasionally showed generalized pustular flares. During this time, dyslipidemia and psoriatic spondyloarthropathy were diagnosed. She had a body mass index of 25.22. Up to 5 biopsy specimens of the cutaneous lesions were taken and analyzed, which showed histopathologic findings indicative of pustular psoriasis. A mutation analysis of the IL-36 receptor antagonist gene was performed with negative results. The patient was treated with acitretin (0.5-1 mg/kg/d), ciclosporin, methotrexate, and psoralen and ultraviolet A monotherapy, achieving only a partial response, particularly with acitretin. Treatment with infliximab in combination with acitretin was started in October 2007. This treatment failed to control the disease, and infliximab was changed to adalimumab, achieving an almost complete response.[@bib1] The patient remained under this combination therapy for 19 months, but unfortunately, she lost the response. Because of the severity of the annular pustular flares, ustekinumab, etanercept, and golimumab were tried successively, always in combination with acitretin (up to 50 mg/d), although the response of psoriasis was very poor. In March 2016, treatment with secukinumab was started (300 mg at baseline, 1, 2, 3, and 4 weeks, and monthly afterward) in combination with acitretin (35 mg/d). At baseline, she presented severe annular pustular lesions, particularly on the trunk and upper and lower extremities: Pustular Psoriasis Area and Severity Index (PPASI), 15; body surface area (BSA), 15%; Patient Global Psoriasis Assessment, 7; Euroqol, 50; Dermatology Life Quality Index (DLQI), 12; and arthritis Visual Analog Scale (VAS), 6 ([Fig 1](#fig1){ref-type="fig"}). She presented a dramatic improvement (at 1 month: PPASI, 1; BSA, 1%; Patient Global Psoriasis Assessment, 1; Euroqol, 80; DLQI, 6; and arthritis VAS, 4), and at 3 months the patient had a complete clearing of the pustular psoriasis ([Fig 2](#fig2){ref-type="fig"}). To date, after 20 months of continuous treatment, the patient remains cleared despite tapering of acitretin to 10 mg/d (PPASI, 0; DLQI, 2). Only the joint symptomatology remains (arthritis VAS, 3). No adverse events were reported.Fig 1Annular pustular lesions before treatment.Fig 2Lesions 3 months after treatment with secukinumab.

Discussion {#sec3}
==========

Annular pustular psoriasis is a rare form of psoriasis excluded from clinical trials. In a review of the literature about the treatment of pustular psoriasis with secukinumab, we found 3 case reports of GPP,[@bib2], [@bib3], [@bib4] 2 case reports of ACH,[@bib5], [@bib6] 1 of PPP,[@bib7] all responding well to this drug, although the effectiveness evaluation system is very variable ([Table I](#tbl1){ref-type="table"}). We also found a Japanese 52-week, open-label, phase III, multicenter, single-arm study on patients with GPP (APP was an exclusion criteria), in which the treatment succeeded in 10 (83.3%) of 12 patients.[@bib8] It has been suggested that IL-17A plays a role in the migration of neutrophils to psoriatic lesions, thereby explaining how inhibition of this cytokine may contribute to the improvement of pustular psoriasis.[@bib9] There are no publications to our knowledge reporting the treatment of APP with secukinumab.Table IPublished reports on the use of secukinumab in different variants of pustular psoriasisCase reportsClinical variantNo. of patientsComedicationOverall responseBöhner et al,[@bib2] 2016GPP1NoGPPASI from 48-8 and BSA from 80-10 at wk 7Imafuku et al,[@bib8] 2016GPP12Cyclosporine (4 pts), etretinate (3 pts, 10-40 mg/d), methotrexate (1 pt), and prednisolone (1 pt)At wk 52: PASI 75, 72.7%; PASI 90, 63.6%; and PASI 100, 27.3%Polesie et al,[@bib3] 2017GPP1NoClear at wk 3Mugheddu et al,[@bib4] 2017GPP1NoPASI 75 was achieved at wk 4, PASI 90 at wk 8, and complete remission at wk 12, maintained at wk 24.Yeung et al,[@bib7] 2016PPP1NoComplete resolution of pustules at wk 3Baron et al,[@bib5] 2017ACH1NoClearance of pustules at 5 dMuggli et al,[@bib6] 2017ACH1NoComplete resolution at 6 wkOur caseAPP1Acitretin (35 mg/d)Complete resolution at 3 mo, maintained after 20 mo[^1]

We emphasize the rapid and complete response to standard doses achieved in our patient, who suffered from a severe APP unresponsive to other conventional and biological therapies. We consider that the role of acitretin in the response of our patient was limited, as it achieved only a partial response when used as monotherapy, and it has been used at high doses (35-50 mg/d) in combination with different biological drugs since 2007 with low success rates.

Further studies are warranted to evaluate the effectiveness and safety of secukinumab in patients with severe APP.
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